Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2025 Financial Guidance; Discontinues Insulin Patch Pump Program; and Announces Restructuring to Streamline Operations and Reduce Costs

Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of...

Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2%...

DARZALEX® (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smouldering multiple myeloma

First subcutaneous anti-CD38 therapy to demonstrate potential to prevent end-organ damage, and extend progression-free survival and overall survival based on...

Slate360 Provides Valuable Insights on the Advantages of Working with a Skilled Healthcare Event Marketing Agency

Benefits of Partnering with an Experienced Healthcare Event Marketing AgencyLas Vegas, NV, Dec. 08, 2024 (GLOBE NEWSWIRE) -- As every...

Global Aerospace’s SM4 Aviation Safety Program Provides Actionable Advice for Enhancing Safety in Your Flight Department